-

Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 40th Annual Virtual Healthcare Conference on Monday, January 10, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal presentation and answer questions about the company at 7:30 a.m. ET.

The event will be webcast simultaneously at http://investor.bms.com with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Bristol Myers Squibb
Media:
media@bms.com
Investor Relations:

Tim Power
609-252-7509
timothy.power@bms.com
Nina Goworek
908-673-9711
nina.goworek@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
Release Versions
$Cashtags

Contacts

Bristol Myers Squibb
Media:
media@bms.com
Investor Relations:

Tim Power
609-252-7509
timothy.power@bms.com
Nina Goworek
908-673-9711
nina.goworek@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)...

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease...

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio...
Back to Newsroom